INDIGO: Obexelimab vs Placebo in Active IgG4-Related Disease (2026) — Trial Summary
INDIGO: Obexelimab vs Placebo in Active IgG4-Related Disease (2026): Phase 3, double-blind, randomized, placebo-controlled trial in adults with active IgG4-related disease. Weekly subcutaneous obexelimab 250 mg versus placebo for 52 weeks; standardized glucocorticoid taper to discontinuation by week
References
- Della-Torre E, Baker MC, Zhang W, et al. Obexelimab for the Treatment of IgG4-Related Disease. N Engl J Med. 2026;395(13):1273-1284. doi:10.1056/NEJMoa2601337